Proteomic profiling of peripheral blood and bronchoalveolar lavage fluid in interstitial lung diseases: An explorative study

Sebastian Majewski, Xing Wu Zhou, Joanna Miłkowska-Dymanowska, Adam Białas, Wojciech Piotrowski, Andrei Malinovschi


This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Proteomic profiling of peripheral blood and bronchoalveolar lavage fluid in interstitial lung diseases: An explorative study

To the Editor:

Interstitial lung diseases (ILDs) are a diverse group of disorders, which differ significantly with respect to etiopathogenesis, clinical, radiological, and pathological picture. Idiopathic pulmonary fibrosis (IPF) and sarcoidosis represent two distinctive examples of ILDs (1).

In IPF, the most significant pathobiological mechanism is linked to the uncontrolled activity of various growth factors resulting in accumulation of myofibroblasts and excessive secretion of extracellular matrix (ECM) proteins, mainly collagen. As a consequence, we observe irreversible and progressive fibrotic lung disease, leading to death within 3–5 years in 50% of patients (2).

On the other hand, sarcoidosis has an immunoinflammatory systemic pathology, with Th1 lymphocyte predominance and excess production of interferon gamma, leading to granuloma formation in various organs. Löfgren’s syndrome is a clinical phenotype of acute sarcoidosis, with a very low risk of lung fibrosis, a high rate of spontaneous resolution, and a good overall prognosis (3).

No studies on simultaneous proteome analysis of serum and bronchoalveolar lavage fluid (BALF) in IPF and sarcoidosis have been published to date. It is noteworthy that the comparative studies of different ILDs using BALF are few (4). Proteomics using panels targeted at various biological processes and other techniques that are more affordable than mass spectrometry, such as proximity extension assay (PEA), are becoming more readily available (5). Briefly, 92 oligonucleotide labeled antibody probe pairs are allowed to bind to their respective target proteins, if present in the sample. A PCR reporter sequence is formed by a proximity-dependent DNA polymerization event. This is then amplified, and subsequently detected and quantified using real-time PCR. The method is validated and provides high sensitivity, specificity and scalability (5). To investigate the utility of PEA technology for BALF samples obtained from patients with ILDs, we performed an explorative study to see if the proteome signature differed in the systemic and lung
compartments between IPF and sarcoidosis, two ILDs with differing predominant mechanisms: fibrotic versus immunoinflammatory.

A total of 25 newly diagnosed ILD patients, including 15 patients with acute sarcoidosis (Löfgren’s syndrome) (median age 40 years (range 25–56), 8 females) and 10 patients with IPF (median age 71 years (range 60–80), 1 female) were studied. Sarcoïdosis and IPF were diagnosed in accordance with international recommendations (2,3). Peripheral blood and BALF samples were collected from all study participants. Bronchoscopy with BALF was performed in accordance with the Polish Respiratory Society recommendations (6). Both serum and BALF supernatant samples were frozen at -80 °C until further proteomic evaluation. Biological samples were analysed with a dedicated proteomics panel for 92 inflammatory proteins using PEA technology (Olink Proteomics, Uppsala, Sweden). The validation information of the protein measurements included in the Olink Inflammation Panel is available from https://www.olink.com/content/uploads/2019/04/Olink-Inflammation-Validation-Data-v3.0.pdf. The complete list of the analysed proteins, see the Olink Proteomics web page for the Inflammation panel (www.olink.com/products/inflammation/biomarkers/). The study protocol was approved by the Ethics Committee of the Medical University of Lodz and the study was conducted in accordance with the Declaration of Helsinki. All participants gave written informed consent for study participation.

For serum, a total of 81 out of 92 proteins were detectable (levels above the limit of detection in at least 75% of the individuals). For BALF, the corresponding number was 49 out of 92 proteins (see Figure 1). All samples passed quality control except one BALF sample from a patient with sarcoidosis. The protein measurements from this BALF sample were removed from further analyses.

Multiple linear regression models were used with each of the 130 proteins (log-transformed) as dependent variables, a patient group (sarcoidosis or IPF) as an independent variable, and adjusted for age, sex, smoking status, and the percentage of lymphocytes in BALF. The results were adjusted for multiple testing using the Benjamini-Hogberg method (7) to control for false discovery rate (FDR). The significance was set to FDR-corrected p values < 0.05.

Significant differences (adjusted for sex, age, smoking status, and lymphocyte percentage) were found for the following 16 proteins in BALF: matrix metalloproteinase (MMP)-1, MMP-10, interleukin (IL)–6, IL-8, transforming growth factor-alpha (TGF-alpha), TNF-
related apoptosis-inducing ligand (TRAIL), osteoprotegerin (OPG), oncostatin M (OSM), chemokine (C-X-C motif) ligand (CXCL) 5, CXCL9, CXCL10, monocyte chemoattractant protein (MCP)-1, MCP-3, MCP-4, macrophage inflammatory protein (MIP)-1β, and eotaxin-1, and for two proteins in serum: stem cell factor (SCF) and CUB-domain containing protein 1 (CDCP1) (Figure 1). All differentially expressed proteins had higher levels in IPF than sarcoidosis, except SCF (Figure 1).

Pearson’s correlation coefficients between the levels of proteins and the percentage of lymphocytes in the sarcoidosis group were tested. A total of 22 proteins were significantly related after adjustments for multiple testing: OSM, IL-12 beta, IL-18, CXCL-11, T-cell surface glycoproteins CD5 and CD8 alpha chain, tumour necrosis factor receptor superfamily member 9 (TNFRSF9) (all proteins measured in BALF, all r values were between 0.8 and 1.0), CXCL-9, CXCL-10, MCP-2, MCP-4, C-C motif chemokine (CCL) 3, CCL4, CCL19, IL-18, IL-18 receptor 1 (IL-18R1), and TNF-beta (TNFB) (IL-18 and TNFB from serum, others from BALF; r values 0.7–0.8), CCL20, TRAIL, OPG, TNF, and hepatocyte growth factor (HGF) (all proteins measured in BALF, r < 0.7).

Pearson’s correlation coefficients between the levels of proteins in BALF and serum were tested for the proteins that could be detected in both BALF and serum (n = 49). One protein was significantly related after adjustments for multiple testing: CCL19.

In the present study, we successfully demonstrated the utility of PEA technology for comprehensive proteomics of BALF and identified differences in the proteome from the lung compartment between systemic immunoinflammatory ILD, sarcoidosis, and fibrotic ILD, IPF. Only two of the 81 measurable proteins in serum differed significantly between sarcoidosis and IPF: SCF and CDCP1. SCF may be crucial for the regulation of inflammatory response in the lungs of patients with ILDs (8). Recent studies suggest that cell surface glycoprotein CDCP1 acts as co-receptor of the TGF-β1 signalling pathway (9); however, its precise role in fibroproliferative diseases remains to be elucidated.

On the other hand, almost one third (16 of 49) of the measurable proteins in BALF differed significantly between sarcoidosis and IPF in our study. Our finding of increased MMP-1 in BALF of patients with IPF is in line with the previous findings of its elevated levels in serum, BALF, and lung tissue in IPF, compared with controls and other forms of ILDs (10). Similarly, increased levels of IL-6 and IL-8 were previously found in patients with various ILDs compared with controls (11). We noted overexpression of TRAIL, OPG, and OSM in
BALF from IPF subjects, which may suggest involvement in the TGF-β1-independent accumulation of ECM proteins in IPF (12–14). We also noted a number of upregulated CC and CXC chemokines which may play significant roles in cell trafficking in pulmonary fibrosis (15).

Further research should include other fibroproliferative ILDs to check whether there are quantitative differences in the proteomes within that heterogeneous group. It seems that PEA technology offers a good alternative to mass spectrometry for proteomics studies utilizing different biological samples, including BALF, and may be applied to study a larger population of patients with ILDs. Some of the proteins of interest might show a different profile if plasma is used instead of serum, but this was outside the scope of the present analyses. The small sample size of the two investigated groups might explain the large confidence intervals noted for the different proteins.

In summary, this small explorative study demonstrates, for the first time, the feasibility and usefulness of PEA technology for BALF proteomics in patients with ILDs. Despite the small sample size, we noted significant differences in levels of BALF proteins between subjects with IPF and those with sarcoidosis. Future, larger, prospective studies should focus on the biological relevance and clinical significance of our findings, with regard to disease prognosis, response to therapy, or novel pathophysiological pathways in ILDs.

Sebastian Majewski¹
Xing Wu Zhou²³
Joanna Miłkowska-Dymanowska¹
Adam Białas⁴
Wojciech Piotrowski¹
Andrei Malinovschi²

¹ Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Poland
² Department of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden
³ Department of Medical Sciences: Respiratory medicine, sleep and allergy, Uppsala University, Uppsala, Sweden
⁴ Department of Pathobiology of Respiratory Diseases, Medical University of Lodz, Lodz, Poland
Funding

Department of Pneumology and Allergy, Medical University of Lodz, Poland; Swedish Heart and Lung Foundation, and Knut and Alice Wallenberg Foundation.

Conflicts of interest

None of the authors has any conflicts of interest to declare with regard to the present work.
Figure legend

Figure 1. Difference in the 92 investigated protein levels expressed between the group of IPF and sarcoidosis expressed as regression coefficient (circle) and 95% confidence interval (line) in BALF (left panel) and serum (right panel). Significant differences (FDR-corrected p-values <0.05) are plotted in red. If the confidence interval is on the right side of the dotted line (0), this means that subjects with IPF had higher levels of that protein than subjects with sarcoidosis. The list of the proteins is found at https://www.olink.com/products/inflammation/.
References

1. Interstitial Lung Diseases [Internet]. European Respiratory Society Journals Ltd; 2009. 406 p. Available from: https://books.ersjournals.com/content/9781904097976/9781904097976


